News Sentiment

VSTM sentiment intelligence

Verastem Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 55 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 5.53 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

76/100 classification confidence.

Company focus 47

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+22.9% over one week, +34.9% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

RBC Capital Reaffirms Outperform Rating For Verastem (VSTM)

Market Reaction

Price moving ahead of tone

59/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 76/100 classification
One-week reaction 22.9% Price confirming higher
Trend fit Trend inactive 34.9% over four weeks
Fair value -19.3% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 31
Negative 11

Relevance

Why the article matched

Direct first
Direct company coverage 47
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 11
TradingView 10
Stock Titan 8
simplywall.st 6
Investing.com 4
Insider Monkey 3
GuruFocus 2
MT Newswires 2

Event Lens

What the news is about

Classified themes
Market update 24
Earnings 18
Analyst action 9
Regulatory and legal 2
Guidance 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-55 of 55
TradingView Direct company coverage

Verastem posts VS-7375 data, reports anti-tumor activity at 400–900 mg QD and 93% CA19-9 drops in mPDAC

Verastem reported positive preliminary data for its drug VS-7375, showing anti-tumor activity at doses of 400–900 mg once daily and significant biomarker responses in metastatic pancreatic ductal adenocarcinoma (mPDAC). Key findings include ongoing dose escalation, anti-tumor act

Tone
Positive 82/100
Event
Market update
Published
23 Jun 2026 20:09
Source
TradingView
Stock Titan Direct company coverage

[144] Verastem, Inc. SEC Filing

Tone
Neutral 50/100
Event
Market update
Published
27 May 2026 07:00
Source
Stock Titan